Ads
related to: biopharma global supply
Search results
Genomic sequencing company expands manufacturing facility - Silicon Valley Business Journal
The Business Journals· 5 days ago“Complete Genomics will integrate supply chain resources from California, the United States, and ...
Reasons to Hold Charles River (CRL) in Your Portfolio Now
Zacks· 3 days agoFree Report) is well-poised for the coming quarters, on the back of its impressive strategic acquisitions. Stabilization of demand trends within the DSA (Discovery and Safety Assessment) arm ...
Reasons to Retain Baxter International (BAX) in Your Portfolio Now
Zacks via Yahoo Finance· 4 days agoBaxter International's (BAX) robust growth across all geographies, along with transformational...
Organigram And This Canadian Cannabis Brand Expand In Europe And Beyond - OrganiGram Holdings...
Benzinga· 5 days agoEurope has become more open-minded about medical and recreational marijuana over the recent years,...
3 Dividend Stocks to Double Up on Right Now
Motley Fool via Yahoo Finance· 3 days agoThe biopharma company has also used a lot of the cash made when COVID-19 was a more serious concern to gobble up smaller drugmakers. Since 2022, Pfizer...
Feds plan for smoother access to RSV infant shot
Politico· 4 days agoJohnson & Johnson struck a deal to buy an experimental skin disease drug for $1.25 billion, BioPharma Dive’s Ben Fidler reports. The FDA issued a priority review voucher to ...
Innovation And Automation Are Driving Forces Behind Next Generation Cell Therapy Manufacturing...
BioresearchOnline· 3 days agoCytiva is tackling industry challenges that hinder patient access and wider adoption of autologous...
Small Business - Picayune Item | Picayune Item
The Picayune Item· 1 day agoXtalks Announces its Life Science Webinar Calendar for June 2024 PR Newswire TORONTO, June 1, 2024 Upcoming free, educational webinars from Xtalks will feature topics on biomarkers, cell and gene therapy, clinical trials, commercialization & HEOR
Biotech faces a reckoning: ‘We've lost our luster in cell therapies’
FierceBiotech· 4 days agoThis story is the first part in a four-part series about cell therapy, created by the Fierce Biotech...
We're initiating a position in a turnaround stock and buying more of another name
CNBC· 5 days agoIn addition, we will buy 100 shares of DuPont at roughly $82.12. Following the trades, Jim Cramer's Charitable Trust will own 100 shares of DOV with a weighting of about 0.60%. Dover is diversified ...
